MedPath

A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

Completed
Conditions
Preterm Birth
Registration Number
NCT02787213
Lead Sponsor
Sera Prognostics, Inc.
Brief Summary

Prospective multicenter observational study to further develop and validate a preterm birth risk predictor, using a preterm cutoff at 37 0/7 weeks gestation and at 35 0/7 weeks gestation. A single maternal peripheral blood sample will be collected for analysis. Data related to potential risk factors for preterm birth will be obtained through maternal interview and review of medical records. Subjects will be followed through the delivery process to assess the course of pregnancy, labor, and to document any related maternal complications. Neonatal outcomes will be gathered from the medical record for up to 28 days of life or discharge, whichever occurs first.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
5011
Inclusion Criteria
  • Subject is 18 years of age or older
  • Subject has singleton gestation
  • Subject is able to provide consent
  • Gestational age is confirmed by a documented crown rump length on an ultrasound performed at the study site within 6 0/7 weeks and 13 6/7 weeks gestation (first trimester)
  • Subject has no signs and/or symptoms of preterm labor and has intact membranes
  • Investigator believes subject is willing to comply with study visits and procedures
  • Investigator believes the subject's delivery data will be available within 15 business days from delivery, and neonatal data will be available for data collection purposes within 15 business days from discharge
Exclusion Criteria
  • The subject has a planned cesarean section or induction of labor prior to 370/7 weeks of gestation

  • The subject has a planned cerclage placement for the current pregnancy

  • There is a known or suspected fetal anomaly or chromosomal abnormality

  • The subject has had a blood transfusion during the current pregnancy

  • The subject has known elevated bilirubin levels (hyperbilirubinemia)

  • The subject has taken or plans to take any of the following medications during the current pregnancy:

    • Progesterone or progesterone-derivative medication after 13 6/7 weeks gestation
    • Enoxaparin, heparin, heparin sodium, low molecular weight heparin after first day of last menstrual period
  • The subject has participated in, or plans to participate in, an interventional treatment study during the current pregnancy

  • The current pregnancy was previously a multiple gestation that is now a single fetus due to reduction, vanishing twin, etc.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Area under the receiver operator characteristic curve (AUROC) for prediction of preterm versus term birth using freshly collected specimens.Up to 30 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

University of California, Irvine Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Orange, California, United States

Ochsner Baptist Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

New Orleans, Louisiana, United States

University of Colorado-Denver

๐Ÿ‡บ๐Ÿ‡ธ

Aurora, Colorado, United States

Denver Health Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Baystate Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Springfield, Massachusetts, United States

University of North Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Chapel Hill, North Carolina, United States

Oregon Health & Sciences University

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Medical University of South Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Greenville Health System

๐Ÿ‡บ๐Ÿ‡ธ

Greenville, South Carolina, United States

UC San Diego Health

๐Ÿ‡บ๐Ÿ‡ธ

San Diego, California, United States

Indiana University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

Thomas Jefferson University Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Regional Obstetrical Consultants

๐Ÿ‡บ๐Ÿ‡ธ

Chattanooga, Tennessee, United States

University of Texas Medical Branch

๐Ÿ‡บ๐Ÿ‡ธ

Galveston, Texas, United States

Maricopa Integrated Health Systems

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

Duke University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Durham, North Carolina, United States

Boston Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Northwestern Memorial Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath